MNG241
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MTORC1_SIGNALING+0.465
- OXIDATIVE_PHOSPHORYLATION+0.460
- E2F_TARGETS+0.411
- DNA_REPAIR+0.355
- MYC_TARGETS_V1+0.353
- G2M_CHECKPOINT+0.351
- PROTEIN_SECRETION+0.340
- PEROXISOME+0.330
- PI3K_AKT_MTOR_SIGNALING+0.328
- ADIPOGENESIS+0.325
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.511
- INFLAMMATORY_RESPONSE-0.407
- WNT_BETA_CATENIN_SIGNALING-0.397
- IL6_JAK_STAT3_SIGNALING-0.356
- PANCREAS_BETA_CELLS-0.353
- ALLOGRAFT_REJECTION-0.326
- KRAS_SIGNALING_UP-0.318
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.315
- APICAL_SURFACE-0.266
- KRAS_SIGNALING_DN-0.262
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A0YT-01A-11R-A109-07 | — | B | 0.884 |
| 2 | TCGA-A8-A06O-01A-11R-A00Z-07 | — | B | 0.875 |
| 3 | R408 | — | — | 0.873 |
| 4 | TCGA-AN-A0AK-01A-21R-A00Z-07 | — | C | 0.869 |
| 5 | R414 | — | — | 0.863 |
| 6 | TCGA-B6-A0WV-01A-11R-A109-07 | — | B | 0.862 |
| 7 | TCGA-46-3768-01A-01R-0980-07 | — | cohortSQ2 | 0.862 |
| 8 | SRR26320065 | — | — | 0.862 |
| 9 | TCGA-A8-A06Z-01A-11R-A00Z-07 | — | B | 0.857 |
| 10 | SJEPD030833_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.856 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MTORC1_SIGNALING | 0.465 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.460 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.411 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.355 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.353 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.351 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| PEROXISOME | 0.330 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.328 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.325 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.322 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.298 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.279 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.207 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.202 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.147 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.122 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.114 | Inavolisib | — uncovered |